Novel insights into serodiagnosis and epidemiology of Erysipelothrix rhusiopathiae, a newly recognized pathogen in muskoxen (Ovibos moschatus).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
10
2019
accepted:
30
03
2020
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
21
7
2020
Statut:
epublish
Résumé
Muskoxen are a key species of Arctic ecosystems and are important for food security and socio-economic well-being of many Indigenous communities in the Arctic and Subarctic. Between 2009 and 2014, the bacterium Erysipelothrix rhusiopathiae was isolated for the first time in this species in association with multiple mortality events in Canada and Alaska, raising questions regarding the spatiotemporal occurrence of the pathogen and its potential impact on muskox populations. We adapted a commercial porcine E. rhusiopathiae enzyme-linked immunosorbent assay to test 958 blood samples that were collected from muskoxen from seven regions in Alaska and the Canadian Arctic between 1976 and 2017. The cut-off between negative and positive results was established using mixture-distribution analysis, a data-driven approach. Based on 818 samples for which a serological status could be determined and with complete information, we calculated trends in sample seroprevalences in population time-series and compared them with population trends in the investigated regions. Overall, 219/818 (27.8%, 95% Confidence Interval: 24.7-31.0) samples were classified as positive for exposure to E. rhusiopathiae. There were large variations between years and regions. Seropositive animals were found among the earliest serum samples tested; 1976 in Alaska and 1991 in Canada. In Alaskan muskoxen, sample seroprevalence increased after 2000 and, in two regions, peak seroprevalences occurred simultaneously with population declines. In one of these regions, concurrent unusual mortalities were observed and E. rhusiopathiae was isolated from muskox carcasses. In Canada, there was an increase in sample seroprevalence in two muskox populations following known mortality events that had been attributed to E. rhusiopathiae. Our results indicate widespread exposure of muskoxen to E. rhusiopathiae in western Canada and Alaska. Although not new to the Arctic, we documented an increased exposure to the pathogen in several regions concurrent with population declines. Understanding causes for the apparent increased occurrence of this pathogen and its association with large scale mortality events for muskoxen is critical to evaluate the implications for wildlife and wildlife-dependent human populations in the Arctic.
Sections du résumé
BACKGROUND
Muskoxen are a key species of Arctic ecosystems and are important for food security and socio-economic well-being of many Indigenous communities in the Arctic and Subarctic. Between 2009 and 2014, the bacterium Erysipelothrix rhusiopathiae was isolated for the first time in this species in association with multiple mortality events in Canada and Alaska, raising questions regarding the spatiotemporal occurrence of the pathogen and its potential impact on muskox populations.
MATERIALS AND METHODS
We adapted a commercial porcine E. rhusiopathiae enzyme-linked immunosorbent assay to test 958 blood samples that were collected from muskoxen from seven regions in Alaska and the Canadian Arctic between 1976 and 2017. The cut-off between negative and positive results was established using mixture-distribution analysis, a data-driven approach. Based on 818 samples for which a serological status could be determined and with complete information, we calculated trends in sample seroprevalences in population time-series and compared them with population trends in the investigated regions.
RESULTS
Overall, 219/818 (27.8%, 95% Confidence Interval: 24.7-31.0) samples were classified as positive for exposure to E. rhusiopathiae. There were large variations between years and regions. Seropositive animals were found among the earliest serum samples tested; 1976 in Alaska and 1991 in Canada. In Alaskan muskoxen, sample seroprevalence increased after 2000 and, in two regions, peak seroprevalences occurred simultaneously with population declines. In one of these regions, concurrent unusual mortalities were observed and E. rhusiopathiae was isolated from muskox carcasses. In Canada, there was an increase in sample seroprevalence in two muskox populations following known mortality events that had been attributed to E. rhusiopathiae.
CONCLUSION
Our results indicate widespread exposure of muskoxen to E. rhusiopathiae in western Canada and Alaska. Although not new to the Arctic, we documented an increased exposure to the pathogen in several regions concurrent with population declines. Understanding causes for the apparent increased occurrence of this pathogen and its association with large scale mortality events for muskoxen is critical to evaluate the implications for wildlife and wildlife-dependent human populations in the Arctic.
Identifiants
pubmed: 32315366
doi: 10.1371/journal.pone.0231724
pii: PONE-D-19-30167
pmc: PMC7173868
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231724Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol Methods. 2013 Nov;193(2):295-303
pubmed: 23835034
Oecologia. 2008 Feb;155(1):101-10
pubmed: 17990003
Methods Mol Biol. 2009;498:157-72
pubmed: 18988025
J Wildl Dis. 1994 Jul;30(3):436-8
pubmed: 7933291
Front Microbiol. 2016 Nov 07;7:1759
pubmed: 27872617
BMC Infect Dis. 2007 Nov 06;7:125
pubmed: 17986335
BMC Vet Res. 2013 Nov 04;9:223
pubmed: 24188616
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12353-8
pubmed: 18719116
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):9031-6
pubmed: 9671799
Parasitol Res. 2014 Aug;113(8):2899-905
pubmed: 24861013
J Vet Diagn Invest. 2004 Mar;16(2):145-9
pubmed: 15053366
Can Vet J. 2015 Jun;56(6):560-3
pubmed: 26028673
BMC Evol Biol. 2005 Oct 06;5:49
pubmed: 16209705
Science. 2009 Jan 9;323(5911):227
pubmed: 18974316
J Wildl Dis. 2011 Jan;47(1):12-20
pubmed: 21269992
Glob Chang Biol. 2013 Nov;19(11):3254-62
pubmed: 23828740
Can Vet J. 1977 Apr;18(4):101-4
pubmed: 861922
Int J Tuberc Lung Dis. 2005 Oct;9(10):1097-104
pubmed: 16229220
J Wildl Dis. 2017 Apr;53(2):311-329
pubmed: 28099077
Int J Tuberc Lung Dis. 2008 Aug;12(8):895-902
pubmed: 18647448
J Clin Microbiol. 1994 May;32(5):1211-6
pubmed: 8051246
BMC Infect Dis. 2019 Mar 25;19(1):282
pubmed: 30909869
J Microbiol Methods. 2012 Oct;91(1):73-9
pubmed: 22820200
Sci Adv. 2018 Jan 17;4(1):eaao2314
pubmed: 29376120
Ecol Appl. 2010 Oct;20(7):2058-74
pubmed: 21049890
Ambio. 2020 Mar;49(3):805-819
pubmed: 31187429
Vet Pathol. 2017 Mar;54(2):258-268
pubmed: 27543449
Curr Biol. 2018 Dec 17;28(24):4022-4028.e5
pubmed: 30528581
J Wildl Dis. 2016 Jul;52(3):719-24
pubmed: 27285415